Is SYRE or KOD more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Kodiak Sciences N/A -273.23% -85.48%

Does the media prefer SYRE or KOD?

In the previous week, Kodiak Sciences had 58 more articles in the media than Spyre Therapeutics. MarketBeat recorded 64 mentions for Kodiak Sciences and 6 mentions for Spyre Therapeutics. Kodiak Sciences' average media sentiment score of 0.59 beat Spyre Therapeutics' score of 0.43 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 17 Very Positive mention(s) 8 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KOD or IMVT?

Kodiak Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.19 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is KOD or IMVT more profitable?

Immunovant's return on equity of -69.59% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -273.23% -85.48% Immunovant N/A -69.59% -62.49%

Does the media favor KOD or IMVT?

In the previous week, Kodiak Sciences had 53 more articles in the media than Immunovant. MarketBeat recorded 64 mentions for Kodiak Sciences and 11 mentions for Immunovant. Kodiak Sciences' average media sentiment score of 0.59 beat Immunovant's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 17 Very Positive mention(s) 8 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to KOD or IONS?

In the previous week, Kodiak Sciences had 59 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 64 mentions for Kodiak Sciences and 5 mentions for Ionis Pharmaceuticals. Kodiak Sciences' average media sentiment score of 0.59 beat Ionis Pharmaceuticals' score of 0.25 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 17 Very Positive mention(s) 8 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KOD or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Kodiak Sciences' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -273.23% -85.48% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to KOD or ALKS?

In the previous week, Kodiak Sciences had 60 more articles in the media than Alkermes. MarketBeat recorded 64 mentions for Kodiak Sciences and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Kodiak Sciences' score of 0.59 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 17 Very Positive mention(s) 8 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kodiak Sciences (KOD) Competitors

$94.45 -4.01 (-4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$94.20 -0.26 (-0.27%)

As of 06:45 PM Eastern

Compare

KOD vs. SYRE, IMVT, IONS, ALKS, and CGON

Should you buy Kodiak Sciences stock or one of its competitors? Kodiak Sciences's main competitors and comparable companies include Spyre Therapeutics (SYRE), Immunovant (IMVT), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kodiak Sciences compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Spyre Therapeutics' return on equity of -30.74% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Kodiak Sciences	N/A	-273.23%	-85.48%

In the previous week, Kodiak Sciences had 58 more articles in the media than Spyre Therapeutics. MarketBeat recorded 64 mentions for Kodiak Sciences and 6 mentions for Spyre Therapeutics. Kodiak Sciences' average media sentiment score of 0.59 beat Spyre Therapeutics' score of 0.43 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	17 Very Positive mention(s)	8 Positive mention(s)	26 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics presently has a consensus target price of $109.71, indicating a potential upside of 18.21%. Kodiak Sciences has a consensus target price of $100.43, indicating a potential upside of 12.05%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Spyre Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Spyre Therapeutics has a beta of 3.1, indicating that its stock price is 210% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Spyre Therapeutics has higher revenue and earnings than Kodiak Sciences. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,170.96	-$155.20M	-$1.95	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Spyre Therapeutics beats Kodiak Sciences on 10 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Immunovant?

Kodiak Sciences (NASDAQ:KOD) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Kodiak Sciences had 53 more articles in the media than Immunovant. MarketBeat recorded 64 mentions for Kodiak Sciences and 11 mentions for Immunovant. Kodiak Sciences' average media sentiment score of 0.59 beat Immunovant's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	17 Very Positive mention(s)	8 Positive mention(s)	26 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Immunovant's return on equity of -69.59% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Immunovant	N/A	-69.59%	-62.49%

Kodiak Sciences currently has a consensus target price of $100.43, suggesting a potential upside of 12.05%. Immunovant has a consensus target price of $44.00, suggesting a potential upside of 30.32%. Given Immunovant's higher possible upside, analysts clearly believe Immunovant is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Kodiak Sciences has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Kodiak Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Summary

Kodiak Sciences beats Immunovant on 7 of the 13 factors compared between the two stocks.

How does Kodiak Sciences compare to Ionis Pharmaceuticals?

Kodiak Sciences (NASDAQ:KOD) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Kodiak Sciences presently has a consensus price target of $100.43, indicating a potential upside of 12.05%. Ionis Pharmaceuticals has a consensus price target of $89.20, indicating a potential upside of 104.50%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Kodiak Sciences has higher earnings, but lower revenue than Ionis Pharmaceuticals. Kodiak Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Ionis Pharmaceuticals	$944M	7.68	-$381.39M	-$3.46	N/A

In the previous week, Kodiak Sciences had 59 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 64 mentions for Kodiak Sciences and 5 mentions for Ionis Pharmaceuticals. Kodiak Sciences' average media sentiment score of 0.59 beat Ionis Pharmaceuticals' score of 0.25 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	17 Very Positive mention(s)	8 Positive mention(s)	26 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kodiak Sciences has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Ionis Pharmaceuticals' return on equity of -111.08% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Kodiak Sciences has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Alkermes?

Kodiak Sciences (NASDAQ:KOD) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Alkermes has a net margin of 3.96% compared to Kodiak Sciences' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Alkermes	3.96%	4.15%	2.19%

Kodiak Sciences has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kodiak Sciences currently has a consensus target price of $100.43, indicating a potential upside of 12.05%. Alkermes has a consensus target price of $54.47, indicating a potential upside of 30.88%. Given Alkermes' stronger consensus rating and higher probable upside, analysts clearly believe Alkermes is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Alkermes has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Alkermes	$1.48B	4.73	$241.66M	$0.38	109.53

In the previous week, Kodiak Sciences had 60 more articles in the media than Alkermes. MarketBeat recorded 64 mentions for Kodiak Sciences and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Kodiak Sciences' score of 0.59 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	17 Very Positive mention(s)	8 Positive mention(s)	26 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alkermes beats Kodiak Sciences on 13 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to CG Oncology?

Kodiak Sciences (NASDAQ:KOD) and CG Oncology (NASDAQ:CGON) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Kodiak Sciences has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Kodiak Sciences presently has a consensus price target of $100.43, suggesting a potential upside of 12.05%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 29.96%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

CG Oncology has higher revenue and earnings than Kodiak Sciences. CG Oncology is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
CG Oncology	$4.04M	1,481.87	-$160.99M	-$2.69	N/A

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kodiak Sciences has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

In the previous week, Kodiak Sciences had 64 more articles in the media than CG Oncology. MarketBeat recorded 64 mentions for Kodiak Sciences and 0 mentions for CG Oncology. Kodiak Sciences' average media sentiment score of 0.59 beat CG Oncology's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Kodiak Sciences	Positive
CG Oncology	Neutral

Summary

CG Oncology beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOD vs. The Competition

Export

Metric	Kodiak Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.94B	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-22.54	12.99	274.61	26.05
Price / Sales	N/A	1,288.54	601.02	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	31.80	16.63	10.92	6.31
Net Income	-$229.97M	-$22.67M	$3.50B	$361.43M
7 Day Performance	191.96%	-3.06%	-2.11%	-1.67%
1 Month Performance	151.87%	-10.76%	-6.34%	-3.94%
1 Year Performance	603.28%	21.10%	8.81%	2.77%

Kodiak Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOD Kodiak Sciences	2.4249 of 5 stars	$94.45 -4.1%	$100.43 +6.3%	+524.7%	$5.94B	N/A	N/A	124	Trending News Analyst Forecast Insider Trade Analyst Revision High Trading Volume
SYRE Spyre Therapeutics	2.1131 of 5 stars	$92.85 +0.9%	$109.69 +18.1%	+446.4%	$8.16B	$890K	N/A	112	Analyst Forecast
IMVT Immunovant	1.8727 of 5 stars	$37.75 +1.5%	$44.00 +16.6%	+105.9%	$7.78B	N/A	N/A	315
IONS Ionis Pharmaceuticals	3.1949 of 5 stars	$45.05 +0.3%	$90.50 +100.9%	-33.1%	$7.46B	$874.09M	N/A	1,402
ALKS Alkermes	3.0833 of 5 stars	$44.03 -0.3%	$54.75 +24.4%	+32.3%	$7.39B	$1.48B	116.00	2,050

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KOD) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kodiak Sciences (KOD) Competitors

KOD vs. SYRE, IMVT, IONS, ALKS, and CGON

How does Kodiak Sciences compare to Spyre Therapeutics?

Summary

How does Kodiak Sciences compare to Immunovant?

Summary

How does Kodiak Sciences compare to Ionis Pharmaceuticals?

Summary

How does Kodiak Sciences compare to Alkermes?

Summary

How does Kodiak Sciences compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kodiak Sciences (KOD) Competitors

KOD vs. SYRE, IMVT, IONS, ALKS, and CGON

How does Kodiak Sciences compare to Spyre Therapeutics?

Is SYRE or KOD more profitable?

Does the media prefer SYRE or KOD?

Do analysts recommend SYRE or KOD?

Which has more volatility and risk, SYRE or KOD?

Which has preferable earnings and valuation, SYRE or KOD?

Do institutionals & insiders believe in SYRE or KOD?

Summary

How does Kodiak Sciences compare to Immunovant?

Do insiders and institutionals have more ownership in KOD or IMVT?

Does the media favor KOD or IMVT?

Is KOD or IMVT more profitable?

Do analysts rate KOD or IMVT?

Which has more risk & volatility, KOD or IMVT?

Which has higher earnings and valuation, KOD or IMVT?

Summary

How does Kodiak Sciences compare to Ionis Pharmaceuticals?

Do analysts recommend KOD or IONS?

Which has better earnings & valuation, KOD or IONS?

Does the media refer more to KOD or IONS?

Is KOD or IONS more profitable?

Which has more risk & volatility, KOD or IONS?

Do insiders & institutionals believe in KOD or IONS?

Summary

How does Kodiak Sciences compare to Alkermes?

Is KOD or ALKS more profitable?

Which has more volatility & risk, KOD or ALKS?

Do insiders & institutionals hold more shares of KOD or ALKS?

Do analysts rate KOD or ALKS?

Which has higher earnings & valuation, KOD or ALKS?

Does the media refer more to KOD or ALKS?

Summary

How does Kodiak Sciences compare to CG Oncology?

Is KOD or CGON more profitable?

Do analysts prefer KOD or CGON?

Which has preferable earnings and valuation, KOD or CGON?

Do insiders and institutionals have more ownership in KOD or CGON?

Which has more volatility & risk, KOD or CGON?

Does the media favor KOD or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools